A quiet but disturbing pattern is emerging behind India’s booming weight-loss trend, and a recent crackdown in Gurugram has brought it into sharp focus. What looks like a routine seizure of counterfeit medicines is, in fact, a window into a far more complex and worrying reality—one where rising demand, limited access, and public desperation are converging to create a dangerous underground market.

Officials from the Haryana drug regulatory agency recently seized counterfeit products falsely labelled as Mounjaro®, a widely discussed injectable drug used for managing type 2 diabetes and increasingly sought after for weight loss. The manufacturer, Eli Lilly and Company (India), confirmed that these seized products were not part of its authorised supply chain and were never produced under its quality standards. Following a detailed investigation, most of the fake stock has now been recovered, and the supply of genuine medicine continues through licensed channels without disruption.

Yet, the incident raises a more uncomfortable question—why are patients turning to such risky alternatives in the first place?

The answer lies in a potent mix of hype and hope. Tirzepatide, the active molecule in Mounjaro®, works by mimicking natural hormones that regulate blood sugar and appetite. In simple terms, it helps people feel full sooner and stabilises glucose levels. Clinical trials published in peer-reviewed journals such as The New England Journal of Medicine have shown substantial weight reduction among users, fuelling its popularity beyond diabetic patients.

But here’s the catch. Access is not always easy. Prescriptions are required. Supplies can be inconsistent. Costs are often high. And in that gap, a parallel market quietly thrives.

“This is a predictable tragedy,” said a senior pharmacovigilance expert familiar with the case, noting that whenever a “miracle” drug captures public imagination, illicit operators are quick to exploit the demand. “People are not just buying medicine—they are buying hope, often without safeguards.”

Eli Lilly echoed concerns around patient safety. “We recognise the efforts of the Haryana regulatory authority in addressing counterfeit medicines and supporting measures aimed at protecting patient safety,” said Winselow Tucker, President and General Manager, Eli Lilly and Company (India). “Lilly takes any act of counterfeiting very seriously. Counterfeit products are not manufactured under approved quality controls and may pose significant risks to patient safety and public health.”

The risks are not theoretical. Unlike regulated medicines, counterfeit drugs are not produced in controlled environments. There are no sterile conditions, no verified ingredients, and no guarantee of dosage accuracy. In practical terms, a patient injecting a fake product could be exposing themselves to infections, allergic reactions, or simply a substance that does nothing at all.

Adding to the confusion is the dual branding of the same molecule. In India, tirzepatide is marketed under two names—Mounjaro® and Yurpeak®. While medically identical, the existence of multiple brand names can create uncertainty among patients, especially those already navigating informal supply routes. For counterfeiters, this confusion becomes an opportunity.

Investigators involved in the Gurugram case described subtle but telling differences between genuine and fake packaging—misspelt labels, missing batch numbers, and slight variations in logos. 

Patients and carers are now being urged to remain alert. Products sourced from unlicensed sellers, damaged packaging, or missing manufacturing details should be treated as red flags. More importantly, experts stress that these drugs should only be used under medical supervision and obtained through authorised pharmacies.

What this episode ultimately reveals is not just a law enforcement success but a systemic vulnerability. A high-demand therapy, limited regulated access, and widespread social pressure around weight have together created fertile ground for exploitation.

Until that imbalance is addressed, the risk will persist—not just in Gurugram, but wherever desperation meets demand.